John A. Barranger focuses on Molecular biology, Glucocerebrosidase, Biochemistry, Pathology and Gene. John A. Barranger has researched Molecular biology in several fields, including Mutation, Glucosylceramidase, Complementary DNA, Viral vector and Fibroblast. While the research belongs to areas of Viral vector, John A. Barranger spends his time largely on the problem of Bone marrow, intersecting his research to questions surrounding Genetic enhancement, Virology, Haematopoiesis and Transplantation.
His research in Glucocerebrosidase intersects with topics in Hepatosplenomegaly, Allele and Neuraminidase. In general Biochemistry, his work in Glucocerebroside, Intracellular and Extracellular is often linked to Lymphocyte activating factor and Latex beads linking many areas of study. In his study, which falls under the umbrella issue of Pathology, Hyperdiploidy and Cytokine genes is strongly linked to Immunology.
John A. Barranger mainly investigates Glucocerebrosidase, Biochemistry, Molecular biology, Enzyme and Disease. His Glucocerebrosidase research is multidisciplinary, incorporating perspectives in Phenotype, Fibroblast and Gaucher's disease. The Molecular biology study combines topics in areas such as Cell culture, Complementary DNA, Genetic enhancement and Antibody, Monoclonal antibody.
He studied Enzyme and Chromatography that intersect with Gel electrophoresis. John A. Barranger has included themes like Clinical trial and Bioinformatics in his Disease study. His work carried out in the field of Enzyme replacement therapy brings together such families of science as Endocrinology and Pediatrics.
His main research concerns Disease, Enzyme replacement therapy, Fabry disease, Pediatrics and Genetic enhancement. His work deals with themes such as Psychotherapist, Clinical trial, Immunology and Intensive care medicine, which intersect with Disease. His studies deal with areas such as Gastroenterology and Endocrinology as well as Enzyme replacement therapy.
His study in Pediatrics is interdisciplinary in nature, drawing from both Metachromatic leukodystrophy, Surgery, Vascular disease and Type 1 Gaucher Disease. Within one scientific family, he focuses on topics pertaining to Transduction under Genetic enhancement, and may sometimes address concerns connected to Molecular biology, Cancer research, Cd34 cells, Clonogenic assay and CD34. His Glucocerebrosidase study results in a more complete grasp of Biochemistry.
His primary areas of investigation include Enzyme replacement therapy, Imiglucerase, Disease, Internal medicine and Genetic enhancement. He has researched Enzyme replacement therapy in several fields, including Surgery and Pediatrics. In the subject of general Disease, his work in Fabry disease is often linked to Correlation, thereby combining diverse domains of study.
His research integrates issues of Gastroenterology and Endocrinology in his study of Internal medicine. His Genetic enhancement research also works with subjects such as
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.
Robert J. Desnick;Roscoe Brady;John Barranger;Allan J. Collins.
Annals of Internal Medicine (2003)
A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease.
Shoji Tsuji;Prabhakara V. Choudary;Brian M. Martin;Barbara K. Stubblefield.
The New England Journal of Medicine (1987)
Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis
Principal Investigator: Christopher H. Evans;Henry J. Mankin;Co-Principal Investigator: Paul D. Robbins;Co-Investigator: Steve C. Ghivizzani.
Human Gene Therapy (1996)
Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation
F.Scott Furbish;Clifford J. Steer;Nancy L. Krett;John A. Barranger.
Biochimica et Biophysica Acta (1981)
Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector.
Toya Ohashi;Sallie Boggs;Paul Robbins;Alfred Bahnson.
Proceedings of the National Academy of Sciences of the United States of America (1992)
Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals.
Shoji Tsuji;Brian M. Martin;John A. Barranger;Barbara K. Stubblefield.
Proceedings of the National Academy of Sciences of the United States of America (1988)
Centrifugal enhancement of retroviral mediated gene transfer.
A B Bahnson;J T Dunigan;B E Baysal;T Mohney.
Journal of Virological Methods (1995)
Relationship between production and release of lymphocyte-activating factor (interleukin 1) by murine macrophages. 1. Effects of various agents
Igal Gery;Igal Gery;Philip Davies;Philip Davies;Julia Derr;Julia Derr;Nancy Krett;Nancy Krett.
Cellular Immunology (1981)
Human gene marker/therapy clinical protocols.
S. A. Rosenberg;R. M. Blaese;M. K. Brenner;A. B. Deisseroth.
Human Gene Therapy (1996)
Skeletal complications of Gaucher disease.
Daniel W. Stowens;Steven L. Teitelbaum;Arnold J. Kahn;John A. Barranger.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: